131 related articles for article (PubMed ID: 21690623)
21. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy.
Beumier M; Roberts JA; Kabtouri H; Hites M; Cotton F; Wolff F; Lipman J; Jacobs F; Vincent JL; Taccone FS
J Antimicrob Chemother; 2013 Dec; 68(12):2859-65. PubMed ID: 23800905
[TBL] [Abstract][Full Text] [Related]
22. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections.
Berthoin K; Ampe E; Tulkens PM; Carryn S
Int J Antimicrob Agents; 2009 Dec; 34(6):555-60. PubMed ID: 19782538
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of vancomycin in patients with severely impaired renal function.
Gonzalez-Martin G; Acuna V; Perez C; Labarca J; Guevara A; Tagle R
Int J Clin Pharmacol Ther; 1996 Feb; 34(2):71-5. PubMed ID: 8929749
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of vancomycin in adult cancer patients.
Al-Kofide H; Zaghloul I; Al-Naim L
J Oncol Pharm Pract; 2010 Dec; 16(4):245-50. PubMed ID: 20015925
[TBL] [Abstract][Full Text] [Related]
25. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function.
Tanaka A; Suemaru K; Otsuka T; Ido K; Nishimiya T; Sakai I; Hasegawa H; Inoue T; Murase M; Yasukawa M; Araki H
Ther Drug Monit; 2007 Apr; 29(2):261-4. PubMed ID: 17417082
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of vancomycin in critically ill patients undergoing continuous venovenous haemodialysis.
Chaijamorn W; Wanakamanee U
Int J Antimicrob Agents; 2014 Oct; 44(4):367-8. PubMed ID: 25127656
[No Abstract] [Full Text] [Related]
27. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
28. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.
Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I
Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752
[TBL] [Abstract][Full Text] [Related]
30. Optimizing initial vancomycin dosing in burn patients.
Elligsen M; Walker SA; Walker SE; Simor A
Burns; 2011 May; 37(3):406-14. PubMed ID: 21095062
[TBL] [Abstract][Full Text] [Related]
31. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg.
Mohammedi I; Descloux E; Argaud L; Le Scanff J; Robert D
Int J Antimicrob Agents; 2006 Mar; 27(3):259-62. PubMed ID: 16472993
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
[TBL] [Abstract][Full Text] [Related]
33. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy.
Barth RH; DeVincenzo N
Kidney Int; 1996 Sep; 50(3):929-36. PubMed ID: 8872968
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition.
D'Agata EM; Green WK; Schulman G; Li H; Tang YW; Schaffner W
Clin Infect Dis; 2001 Jan; 32(1):23-9. PubMed ID: 11112676
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin during the Last Hour of the Hemodialysis Session: A Pharmacokinetic Analysis.
Ghouti-Terki L; Chasseuil E; Rabot N; Paintaud G; François M; Birmelé B; Darrouzain F; Büchler M; Halimi JM; Ternant D
Nephron; 2017; 135(4):261-267. PubMed ID: 28152540
[TBL] [Abstract][Full Text] [Related]
36. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen.
Stamatakis MK; Schreiber JM; Slain D; Gunel E
Am J Health Syst Pharm; 2003 Aug; 60(15):1564-8. PubMed ID: 12951755
[No Abstract] [Full Text] [Related]
38. Comments to Ocampos-Martinez et al. on one of the definitions of kidney failure, and on how to reduce the delay in reaching desired plasma concentrations of vancomycin.
Gerónimo-Pardo M; Lluch OF
Int J Antimicrob Agents; 2012 Nov; 40(5):475-7. PubMed ID: 22871373
[No Abstract] [Full Text] [Related]
39. [Streptogramins and glycopeptides].
Tsuji A
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():360-6. PubMed ID: 17455646
[No Abstract] [Full Text] [Related]
40. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
